Abstracts

789 – Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa

Background Inaccessibility and inaccuracies limit histopathologic diagnosis of Kaposi sarcoma (KS) in Africa. We hypothesized that quantification of KSHV DNA from suspicious skin lesions could distinguish KS from non-KS lesions, thus eventually enabling creation of a diagnostic test that would limit need for histopathologic interpretation. In our earlier training population, quantification of lesional KSHV DNA…

791 – Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment

Background Kaposi sarcoma herpesvirus (KSHV) is the causative agent of Kaposi sarcoma (KS), multicentric Castleman disease (MCD), and KSHV-associated inflammatory cytokine syndrome (KICS). In people with HIV (PWH), KS can occur alone or with MCD or KICS. Liposomal doxorubicin (DOX) and pomalidomide (POM) are FDA-approved therapies for KS alone. A phase I/II study combining POM/DOX…

588 – Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV

Background HIV-1 can be detected in cerebrospinal fluid (CSF) throughout untreated infection but it is unknown how often this is due to local replication in the CNS. In people with HIV-associated dementia (HAD), local replication can generate genetically distinct viral populations in the CNS (compartmentalized) with the unique ability to efficiently infect myeloid lineage cells…

587 – HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV

Background We and others have previously demonstrated that intact, transcriptionally competent HIV genomes persist within the brain of virally suppressed people with HIV (PWH). Long terminal repeats (LTRs) isolated from the brain of non-virally suppressed PWH are genetically distinct from those isolated in matched peripheral tissue and have a reduced responsiveness to select latency reversing…

496 – Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers

Background Elite controllers maintain undetectable levels of HIV replication in the absence of antiretroviral treatment and are considered as a model for a cure of HIV infection. Recent studies suggest distinct viral reservoir characteristics in blood in such persons, however, viral reservoirs in lymphoid tissues from elite controllers remain largely unexplored. Methods Paired samples of…

582 – Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART

Background HIV-1 cure strategies require a comprehensive understanding of cellular phenotype of HIV tissue reservoirs for effective and selective targeting. While recent data have demonstrated the highly heterogeneous nature of peripheral blood CD4+ T cells subsets comprising the HIV reservoir of antiretroviral therapy (ART) treated people with HIV (PWH), CD4+ T follicular helper (Tfh) cells…

498 – Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures

Background Elimination of latently HIV-infected cells remain the biggest challenge to reach a cure. Current immunotherapy approaches have focused on targeting the adaptive arm of the immune system, such as therapeutic vaccines and the passive transfer of broadly neutralizing antibodies. Recent studies showed that epigenetic reprogramming of innate myeloid cells triggered by adjuvants promoted protective…

495 – Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription

Background It remains unclear how HIV transcription varies with timing of ART initiation, duration of ART, and elite controller status. Methods To investigate these questions, we performed a blinded, cross-sectional analysis of 98 PBMC samples from 36 Reservoir Assay Validation and Evaluation Network (RAVEN) program participants, including 4 ART-naïve elite controllers and 32 ART-suppressed participants with HIV…